Current standards, variations, and pitfalls for the determination of constitutive TSHR activity in vitro

Methods in Enzymology

Volumn 485, Issue C, 2010, Pages 421-436

  Mueller, Sandra ^a   Jaeschke, Holger ^a   Paschke, Ralf ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; THYROTROPIN I 125; THYROTROPIN RECEPTOR;

BINDING ASSAY; BOOK; CALCULATION; CELL CYCLE; DIAGNOSTIC ERROR; FALSE POSITIVE RESULT; FLUORESCENCE ACTIVATED CELL SORTING; HORMONE DETERMINATION; HUMAN; IN VITRO STUDY; LINEAR REGRESSION ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECIFIC CONSTITUTIVE ACTIVITY; STANDARD; TRANSIENT TRANSFECTION;

EID: 78049520769     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381296-4.00023-3     Document Type: Chapter

References (50)

1. Agretti P., De Marco G., Collecchi P., Chiovato L., Vitti P., Pinchera A., Tonacchera M. Proper targeting and activity of a nonfunctioning thyroid-stimulating hormone receptor (TSHr) combining an inactivating and activating TSHr mutation in one receptor. Eur. J. Biochem. 2003, 270:3839-3847.
2. Arseven O.K., Wilkes W.P., Jameson J.L., Kopp P. Substitutions of tyrosine 601 in the human thyrotropin receptor result in increase or loss of basal activation of the cyclic adenosine monophosphate pathway and disrupt coupling to Gq/11. Thyroid 2000, 10:3-10.
3. Ballesteros J.A., Jensen A.D., Liapakis G., Rasmussen S.G., Shi L., Gether U., Javitch J.A. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 2001, 276:29171-29177.
4. Biebermann H., Schoneberg T., Schulz A., Krause G., Gruters A., Schultz G., Gudermann T. A conserved tyrosine residue (Y601) in transmembrane domain 5 of the human thyrotropin receptor serves as a molecular switch to determine G-protein coupling. FASEB J. 1998, 12:1461-1471.
5. Cetani F., Tonacchera M., Vassart G. Differential effects of NaCl concentration on the constitutive activity of the thyrotropin and the luteinizing hormone/chorionic gonadotropin receptors. FEBS Lett. 1996, 378:27-31.
6. Claeysen S., Govaerts C., Lefort A., Van Sande J., Costagliola S., Pardo L., Vassart G. A conserved Asn in TM7 of the thyrotropin receptor is a common requirement for activation by both mutations and its natural agonist. FEBS Lett. 2002, 517:195-200.
7. Claus M., Jaeschke H., Kleinau G., Neumann S., Krause G., Paschke R. A hydrophobic cluster in the center of the third extracellular loop is important for thyrotropin receptor signaling. Mol. Endocrinol. 2005, 146:5197-5203.
8. De Leener A., Montanelli L., Van Durme J., Chae H., Smits G., Vassart G., Costagliola S. Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J. Clin. Endocrinol. Metab. 2006, 91:555-562.
9. Dufau M.L. The luteinizing hormone receptor. Annu. Rev. Physiol. 1998, 60:461-496.
10. Duprez L., Parma J., Costagliola S., Hermans J., Van Sande J., Dumont J.E., Vassart G. Constitutive activation of the TSH receptor by spontaneous mutations affecting the N-terminal extracellular domain. FEBS Lett. 1997, 409:469-474.
11. Duprez L., Parma J., Van Sande J., Rodien P., Dumont J.E., Vassart G., Abramowicz M. TSH receptor mutations and thyroid disease. Trends Endocrinol. Metab. 1998, 9:133-140.
12. Eggerickx D., Denef J.F., Labbe O., Hayashi Y., Refetoff S., Vassart G., Parmentier M., Libert F. Molecular cloning of an orphan G-protein-coupled receptor that constitutively activates adenylate cyclase. Biochem. J. 1995, 309(Pt. 3):837-843.
13. Fuhrer D., Holzapfel H.P., Wonerow P., Scherbaum W.A., Paschke R. Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J. Clin. Endocrinol. Metab. 1997, 82:3885-3891.
14. Fuhrer D., Wonerow P., Willgerodt H., Paschke R. Identification of a new thyrotropin receptor germline mutation (Leu629Phe) in a family with neonatal onset of autosomal dominant nonautoimmune hyperthyroidism. J. Clin. Endocrinol. Metab. 1997, 82:4234-4238.
15. Govaerts C., Lefort A., Costagliola S., Wodak S.J., Ballesteros J.A., Van Sande J., Pardo L., Vassart G. A conserved Asn in transmembrane helix 7 is an on/off switch in the activation of the thyrotropin receptor. J. Biol. Chem. 2001, 276:22991-22999.
16. Gozu H., Avsar M., Bircan R., Claus M., Sahin S., Sezgin O., Deyneli O., Paschke R., Cirakoglu B., Akalin S. Two novel mutations in the sixth transmembrane segment of the thyrotropin receptor gene causing hyperfunctioning thyroid nodules. Thyroid 2005, 15:389-397.
17. Gruters A., Schoneberg T., Biebermann H., Krude H., Krohn H.P., Dralle H., Gudermann T. Severe congenital hyperthyroidism caused by a germ-line neo mutation in the extracellular portion of the thyrotropin receptor. J. Clin. Endocrinol. Metab. 1998, 83:1431-1436.
18. Hjorth S.A., Orskov C., Schwartz T.W. Constitutive activity of glucagon receptor mutants. Mol. Endocrinol. 1998, 12:78-86.
19. Ho S.C., Van Sande J., Lefort A., Vassart G., Costagliola S. Effects of mutations involving the highly conserved S281HCC motif in the extracellular domain of the thyrotropin (TSH) receptor on TSH binding and constitutive activity. Mol. Endocrinol. 2001, 142:2760-2767.
20. Holzapfel H.P., Fuhrer D., Wonerow P., Weinland G., Scherbaum W.A., Paschke R. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. J. Clin. Endocrinol. Metab. 1997, 82:4229-4233.
21. Jaeschke H., Neumann S., Kleinau G., Mueller S., Claus M., Krause G., Paschke R. An aromatic environment in the vicinity of serine 281 is a structural requirement for thyrotropin receptor function. Mol. Endocrinol. 2006, 147:1753-1760.
22. Jaeschke H., Mueller S., Eszlinger M., Paschke R. Lack of in vitro constitutive activity for three previously reported TSH-receptor (TSHR)-mutations identified in patiens with nonautoimmune hyperthyroidism. Clin. Endocrinol. 2010, (Oxf) in press.
23. Kleinau G., Brehm M., Wiedemann U., Labudde D., Leser U., Krause G. Implications for molecular mechanisms of glycoprotein hormone receptors using a new sequence-structure-function analysis resource. Mol. Endocrinol. 2007, 21:574-580.
24. Kleinau G., Jaeschke H., Mueller S., Raaka B.M., Neumann S., Paschke R., Krause G. Evidence for cooperative signal triggering at the extracellular loops of the TSH receptor. FASEB J. 2007, 22:2798-2808.
25. Liebmann C. G protein-coupled receptors and their signaling pathways: Classical therapeutical targets susceptible to novel therapeutic concepts. Curr. Pharm. Des. 2004, 10:1937-1958.
26. Montanelli L., Van Durme J.J., Smits G., Bonomi M., Rodien P., Devor E.J., Moffat-Wilson K., Pardo L., Vassart G., Costagliola S. Modulation of ligand selectivity associated with activation of the transmembrane region of the human follitropin receptor. Mol. Endocrinol. 2004, 18:2061-2073.
27. Mueller S., Kleinau G., Jaeschke H., Neumann S., Krause G., Paschke R. Significance of ectodomain cysteine boxes 2 and 3 for the activation mechanism of the thyroid-stimulating hormone receptor. J. Biol. Chem. 2006, 281:31638-31646.
28. Mueller S., Gozu H.I., Bircan R., Jaeschke H., Eszlinger M., Lueblinghoff J., Krohn K., Paschke R. Cases of borderline in vitro constitutive thyrotropin receptor activity: How to decide whether a thyrotropin receptor mutation is constitutively active or not?. Thyroid 2009, 19:765-773.
29. Neumann S., Krause G., Chey S., Paschke R. A free carboxylate oxygen in the side chain of position 674 in transmembrane domain 7 is necessary for TSH receptor activation. Mol. Endocrinol. 2001, 15:1294-1305.
30. Neumann S., Claus M., Paschke R. Interactions between the extracellular domain and the extracellular loops as well as the 6th transmembrane domain are necessary for TSH receptor activation. Eur. J. Endocrinol. 2005, 152:625-634.
31. Neumann S., Krause G., Claus M., Paschke R. Structural determinants for g protein activation and selectivity in the second intracellular loop of the thyrotropin receptor. Mol. Endocrinol. 2005, 146:477-485.
32. Niepomniszcze H., Suarez H., Pitoia F., Pignatta A., Danilowicz K., Manavela M., Elsner B., Bruno O.D. Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes. Thyroid 2006, 16:497-503.
33. Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., Mockel J., Dumont J., Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993, 365:649-651.
34. Parma J., Duprez L., Van Sande J., Paschke R., Tonacchera M., Dumont J., Vassart G. Constitutively active receptors as a disease-causing mechanism. Mol. Cell. Endocrinol. 1994, 100:159-162.
35. Parma J., Van Sande J., Swillens S., Tonacchera M., Dumont J., Vassart G. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: Identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades. Mol. Endocrinol. 1995, 9:725-733.
36. Parma J., Duprez L., Van Sande J., Hermans J., Rocmans P., Van Vliet G., Costagliola S., Rodien P., Dumont J.E., Vassart G. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J. Clin. Endocrinol. Metab. 1997, 82:2695-2701.
37. Pellissier L.P., Sallander J., Campillo M., Gaven F., Queffeulou E., Pillot M., Dumuis A., Claeysen S., Bockaert J., Pardo L. Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors. Mol. Pharmacol. 2009, 75:982-990.
38. Rosenbaum D.M., Rasmussen S.G., Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature 2009, 459:356-363.
39. Russo D., Wong M.G., Costante G., Chiefari E., Treseler P.A., Arturi F., Filetti S., Clark O.H. A Val 677 activating mutation of the thyrotropin receptor in a Hurthle cell thyroid carcinoma associated with thyrotoxicosis. Thyroid 1999, 9:13-17.
40. Russo D., Betterle C., Arturi F., Chiefari E., Girelli M.E., Filetti S. A novel mutation in the thyrotropin (TSH) receptor gene causing loss of TSH binding but constitutive receptor activation in a family with resistance to TSH. J. Clin. Endocrinol. Metab. 2000, 85:4238-4242.
41. Seifert R., Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: Cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2002, 366:381-416.
42. Simoni M., Gromoll J., Nieschlag E. The follicle-stimulating hormone receptor: Biochemistry, molecular biology, physiology, and pathophysiology. Endocr. Rev. 1997, 18:739-773.
43. Smit M.J., Vischer H.F., Bakker R.A., Jongejan A., Timmerman H., Pardo L., Leurs R. Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annu. Rev. Pharmacol. Toxicol. 2007, 47:53-87.
44. Szkudlinski M.W., Fremont V., Ronin C., Weintraub B.D. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol. Rev. 2002, 82:473-502.
45. Tonacchera M., Van Sande J., Cetani F., Swillens S., Schvartz C., Winiszewski P., Portmann L., Dumont J.E., Vassart G., Parma J. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J. Clin. Endocrinol. Metab. 1996, 81:547-554.
46. Tonacchera M., Chiovato L., Pinchera A., Agretti P., Fiore E., Cetani F., Rocchi R., Viacava P., Miccoli P., Vitti P. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma. J. Clin. Endocrinol. Metab. 1998, 83:492-498.
47. Urizar E., Claeysen S., Deupi X., Govaerts C., Costagliola S., Vassart G., Pardo L. An activation switch in the rhodopsin family of G protein coupled receptors: The thyrotropin receptor. J. Biol. Chem. 2005, 280(17):17135-17141.
48. Van Sande J., Swillens S., Gerard C., Allgeier A., Massart C., Vassart G., Dumont J.E. In Chinese hamster ovary K1 cells dog and human thyrotropin receptors activate both the cyclic AMP and the phosphatidylinositol 4, 5-bisphosphate cascades in the presence of thyrotropin and the cyclic AMP cascade in its absence. Eur. J. Biochem. 1995, 229:338-343.
49. Vlaeminck-Guillem V., Ho S.C., Rodien P., Vassart G., Costagliola S. Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol. Endocrinol. 2002, 16:736-746.
50. Wonerow P., Chey S., Fuhrer D., Holzapfel H.P., Paschke R. Functional characterization of five constitutively activating thyrotrophin receptor mutations. Clin. Endocrinol. (Oxf) 2000, 53:461-468.